Critical Analysis: Keros Therapeutics (KROS) versus Its Competitors

Keros Therapeutics (NASDAQ:KROS) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Keros Therapeutics to similar businesses based on the strength of its analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Valuation and Earnings

This table compares Keros Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Keros Therapeutics	$244.06 million	$87.01 million	-3.64
Keros Therapeutics Competitors	$702.34 million	$9.48 million	-18.82

Keros Therapeutics’ peers have higher revenue, but lower earnings than Keros Therapeutics. Keros Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Keros Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Keros Therapeutics’ peers have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.

Profitability

This table compares Keros Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-21.85%	-19.83%
Keros Therapeutics Competitors	-12,323.33%	-195.91%	-30.60%

Analyst Ratings

This is a summary of recent ratings for Keros Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1	2	3	1	2.57
Keros Therapeutics Competitors	9874	15294	45656	1600	2.54

Keros Therapeutics currently has a consensus target price of $20.00, suggesting a potential upside of 94.93%. As a group, “Biotechnology” companies have a potential upside of 126.09%. Given Keros Therapeutics’ peers higher probable upside, analysts plainly believe Keros Therapeutics has less favorable growth aspects than its peers.

Institutional and Insider Ownership

71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 12.6% of Keros Therapeutics shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Keros Therapeutics beats its peers on 9 of the 13 factors compared.

About Keros Therapeutics

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious medical conditions by modulating signaling pathways in the transforming growth factor beta (TGF-β) protein family. Its research has centered on disorders involving blood-cell production and muscle function. The company’s pipeline has included elritercept, an investigational therapy designed to address anemia and other complications associated with blood disorders, as well as candidates developed for muscle-related conditions.